2/26
05:33 pm
kymr
Kymera Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Kymera Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
05:03 pm
kymr
Kymera Therapeutics (KYMR) had its "overweight" rating reaffirmed by Morgan Stanley.
Low
Report
Kymera Therapeutics (KYMR) had its "overweight" rating reaffirmed by Morgan Stanley.
2/26
02:11 pm
kymr
Kymera Therapeutics (KYMR) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Medium
Report
Kymera Therapeutics (KYMR) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
2/26
01:58 pm
kymr
Kymera Therapeutics (KYMR) had its price target lowered by BTIG Research from $138.00 to $134.00. They now have a "buy" rating on the stock.
Medium
Report
Kymera Therapeutics (KYMR) had its price target lowered by BTIG Research from $138.00 to $134.00. They now have a "buy" rating on the stock.
2/26
11:52 am
kymr
Kymera Therapeutics (KYMR) had its price target raised by Piper Sandler from $125.00 to $140.00. They now have an "overweight" rating on the stock.
Medium
Report
Kymera Therapeutics (KYMR) had its price target raised by Piper Sandler from $125.00 to $140.00. They now have an "overweight" rating on the stock.
2/26
07:32 am
kymr
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update [Yahoo! Finance]
High
Report
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update [Yahoo! Finance]
2/26
07:00 am
kymr
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Medium
Report
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
2/24
07:00 am
kymr
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
Low
Report
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
2/19
07:34 am
kymr
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 [Yahoo! Finance]
Low
Report
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 [Yahoo! Finance]
2/19
07:00 am
kymr
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Low
Report
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
2/4
07:18 am
kymr
Kymera Therapeutics to Participate in Upcoming February Investor Conferences [Yahoo! Finance]
Low
Report
Kymera Therapeutics to Participate in Upcoming February Investor Conferences [Yahoo! Finance]
2/4
07:00 am
kymr
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
Low
Report
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
2/3
08:03 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $138.00 price target on the stock.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $138.00 price target on the stock.
1/31
07:03 pm
kymr
Kymera Starts Phase 2b Asthma Trial Testing Oral STAT6 Degrader KT-621 [Yahoo! Finance]
Medium
Report
Kymera Starts Phase 2b Asthma Trial Testing Oral STAT6 Degrader KT-621 [Yahoo! Finance]
1/30
12:27 pm
kymr
KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate [Yahoo! Finance]
Low
Report
KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate [Yahoo! Finance]
1/29
07:31 am
kymr
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader [Yahoo! Finance]
Medium
Report
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader [Yahoo! Finance]
1/29
07:00 am
kymr
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
Medium
Report
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
1/27
07:02 pm
kymr
Kymera Therapeutics (NASDAQ:KYMR) was given a new $133.00 price target on by analysts at Barclays PLC.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) was given a new $133.00 price target on by analysts at Barclays PLC.
1/15
11:52 am
kymr
Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside [Yahoo! Finance]
Medium
Report
Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside [Yahoo! Finance]
1/15
08:02 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $138.00 price target on the stock.
Medium
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $138.00 price target on the stock.
1/13
07:00 am
kymr
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
Low
Report
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
1/12
01:51 pm
kymr
Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why [Yahoo! Finance]
Low
Report
Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why [Yahoo! Finance]
1/7
01:33 pm
kymr
Is Kymera Therapeutics (KYMR) Balancing Pipeline Ambition and Execution Risk After New KT-621 Milestone? [Yahoo! Finance]
Low
Report
Is Kymera Therapeutics (KYMR) Balancing Pipeline Ambition and Execution Risk After New KT-621 Milestone? [Yahoo! Finance]
1/6
07:00 am
kymr
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
Low
Report
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
12/22
09:02 am
kymr
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at B. Riley.
Low
Report
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at B. Riley.